Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC

◇ RESEARCH

Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials)